Drugs |
PT |
N |
ROR
(95% two-sided CI)
|
PRR
(χ2)
|
IC
(95% two-sided CI)
|
EBGM
(95% one-sided CI)
|
Drugs |
PT |
N |
ROR
(95% two-sided CI)
|
PRR
(χ2)
|
IC
(95% two-sided CI)
|
EBGM
(95% one-sided
CI)
|
Cabozantiniba
|
Blood pressure inadequately controlled |
940 |
282.9
(262.45,304.94)
|
267.52
(189269.04)
|
59.66
(55.35,64.31)
|
60287401469.68
(60287401469.68)
|
Sorafeniba
|
Hypertension |
1008 |
7.33
(6.88,7.82)
|
6.97
(5155.99)
|
64.74
(60.73,69)
|
2181489196.28
(2181489196.28)
|
|
Dry gangrene |
440 |
6883.12
(5198.37,9113.87)
|
6707.38
(327829.76)
|
55.59
(41.98,73.61)
|
221538384975.11
(221538384975.11)
|
|
Atrial fibrillation |
150 |
1.82
(1.55,2.14)
|
1.81
(54.61)
|
61.17
(52.08,71.85)
|
570144491.93
(570144491.93)
|
|
Superficial vein thrombosis |
143 |
46.28
(39.08,54.8)
|
45.9
(5956.13)
|
56.45
(47.67,66.84)
|
12936474658.03
(12936474658.03)
|
|
Haemorrhage |
118 |
1.53
(1.28,1.83)
|
1.53
(21.45)
|
60.73
(50.66,72.79)
|
480576781.18
(480576781.18)
|
|
Sinus tachycardia |
72 |
5.84
(4.63,7.36)
|
5.82
(285.41)
|
57.38
(45.49,72.38)
|
1717187481.63
(1717187481.63)
|
|
Deep
vein thrombosis |
92 |
1.44
(1.18,1.77)
|
1.44
(12.5)
|
60.09
(48.95,73.77)
|
454279143.52
(454279143.52)
|
|
Cardiac discomfort |
51 |
45.14
(34.04,59.85)
|
45.01
(2082.97)
|
53.5
(40.35,70.94)
|
12698066771.18
(12698066771.18)
|
|
Cardiac failure |
91 |
1.31
(1.06,1.61)
|
1.31
(6.57)
|
60.2
(48.99,73.98)
|
411702241.09
(411702241.09)
|
|
Hypoperfusion |
43 |
50.97
(37.45,69.37)
|
50.85
(1981.31)
|
52.84
(38.83,71.91)
|
14251222570.71
(14251222570.71)
|
|
Acute myocardial infarction |
65 |
2.22
(1.74,2.84)
|
2.22
(43.52)
|
58.47
(45.81,74.62)
|
698464980.44
(698464980.44)
|
|
Cardiac dysfunction |
43 |
22.89
(16.9,31)
|
22.83
(873.97)
|
53.95
(39.83,73.06)
|
6607225260.89
(6607225260.89)
|
|
Flushing |
61 |
1.81
(1.41,2.33)
|
1.81
(22.07)
|
58.58
(45.55,75.34)
|
569596145.82
(569596145.82)
|
|
Cardiac failure acute |
30 |
5.92
(4.13,8.47)
|
5.91
(121.47)
|
54.83
(38.28,78.55)
|
1743684816.44
(1743684816.44)
|
|
Arrhythmia |
61 |
1.43
(1.11,1.84)
|
1.43
(7.93)
|
58.92
(45.81,75.77)
|
450778645.54
(450778645.54)
|
|
Cardiac aneurysm |
22 |
24.82
(16.24,37.94)
|
24.79
(487.91)
|
51.9
(33.95,79.33)
|
7158061394.43
(7158061394.43)
|
|
Blood pressure fluctuation |
39 |
2.42
(1.76,3.31)
|
2.41
(32.18)
|
56.87
(41.52,77.91)
|
758858171
(758858171)
|
|
Labile hypertension |
20 |
85.22
(53.78,135.02)
|
85.12
(1509.4)
|
49.94
(31.52,79.13)
|
22970569870.69
(22970569870.69)
|
|
Pericardial effusion |
31 |
1.61
(1.13,2.3)
|
1.61
(7.23)
|
56.79
(39.91,80.81)
|
508091449.33
(508091449.33)
|
|
Distributive shock |
20 |
26.52
(16.99,41.4)
|
26.49
(475.56)
|
51.53
(33.01,80.45)
|
7633405301.59
(7633405301.59)
|
|
Myocardial ischaemia |
29 |
2.41
(1.68,3.48)
|
2.41
(23.91)
|
56.02
(38.9,80.68)
|
758735245.6
(758735245.6)
|
|
Supraventricular tachycardia |
20 |
2.38
(1.53,3.69)
|
2.38
(15.89)
|
54.97
(35.43,85.28)
|
704140932.61
(704140932.61)
|
|
Cardiomyopathy |
29 |
2.12
(1.47,3.05)
|
2.12
(17.1)
|
56.21
(39.03,80.94)
|
666806456.55
(666806456.55)
|
|
Right ventricular hypertrophy |
18 |
21.74
(13.61,34.71)
|
21.71
(346.73)
|
51.51
(32.25,82.26)
|
6291938703.71
(6291938703.71)
|
|
Left
ventricular dysfunction |
27 |
4.66
(3.19,6.8)
|
4.65
(77.02)
|
54.87
(37.58,80.12)
|
1459822016.31
(1459822016.31)
|
|
Orthostatic hypertension |
15 |
45.44
(27.02,76.42)
|
45.4
(617.91)
|
49.96
(29.71,84.01)
|
12802946049.5
(12802946049.5)
|
|
Circulatory collapse |
26 |
1.57
(1.07,2.3)
|
1.57
(5.33)
|
56.33
(38.33,82.78)
|
493489672.02
(493489672.02)
|
|
Hypovolaemic shock |
12 |
2.93
(1.66,5.16)
|
2.93
(15.18)
|
53.2
(30.17,93.78)
|
867140677.64
(867140677.64)
|
|
Cardiotoxicity |
24 |
3.95
(2.64,5.89)
|
3.94
(52.45)
|
54.77
(36.66,81.81)
|
1237677312.35
(1237677312.35)
|
|
Hyperaemia |
9 |
5.9
(3.06,11.36)
|
5.9
(36.33)
|
51.36
(26.66,98.96)
|
1740167686.48
(1740167686.48)
|
|
Internal haemorrhage |
24 |
2.3
(1.54,3.44)
|
2.3
(17.63)
|
55.54
(37.2,82.93)
|
724135762.42
(724135762.42)
|
|
Phlebitis superficial |
8 |
21.51
(10.66,43.4)
|
21.5
(152.45)
|
49.18
(24.37,99.23)
|
6230767077.43
(6230767077.43)
|
|
Acute coronary syndrome |
23 |
2.81
(1.87,4.24)
|
2.81
(26.75)
|
55.13
(36.6,83.04)
|
883811563.27
(883811563.27)
|
|
Peripheral artery thrombosis |
8 |
7.27
(3.62,14.58)
|
7.27
(42.87)
|
50.72
(25.29,101.74)
|
2141617040.58
(2141617040.58)
|
|
Aortic dissection |
21 |
5.08
(3.31,7.8)
|
5.07
(68.28)
|
54.02
(35.17,82.98)
|
1591058105.9
(1591058105.9)
|
|
Cardiorenal syndrome |
6 |
13.42
(5.99,30.06)
|
13.41
(67.85)
|
49.02
(21.88,109.82)
|
3924892647.2
(3924892647.2)
|
|
Shock
haemorrhagic |
21 |
3.1
(2.02,4.76)
|
3.1
(29.7)
|
54.73
(35.65,84.03)
|
973126858.13
(973126858.13)
|
|
Thrombophlebitis migrans |
5 |
40.71
(16.59,99.9)
|
40.7
(184.66)
|
46.94
(19.13,115.18)
|
11538457550.79
(11538457550.79)
|
|
Supraventricular tachycardia |
21 |
2.42
(1.58,3.72)
|
2.42
(17.48)
|
55.08
(35.88,84.56)
|
761703054.23
(761703054.23)
|
Drugs |
PT |
N |
ROR
(95% two-sided
CI)
|
PRR
(χ2)
|
IC
(95% two-sided CI)
|
EBGM
(95% one-sided CI)
|
Drugs |
PT |
N |
ROR
(95% two-sided CI)
|
PRR
(χ2)
|
IC
(95% two-sided CI)
|
EBGM
(95% one-sided
CI)
|
Lenvatinib |
Hypertension |
163 |
7.98
(6.81,9.35)
|
7.55
(932.22)
|
59.36
(50.65,69.56)
|
52381539.17
(52381539.17)
|
Regorafenib |
Hypertension |
471 |
8.06
(7.35,8.85)
|
7.62
(2722.53)
|
62.41
(56.84,68.52)
|
433925901.61
(433925901.61)
|
|
Myocardial infarction |
39 |
1.46
(1.06,2)
|
1.45
(5.53)
|
57.61
(41.99,79.03)
|
10084133.57
(10084133.57)
|
|
Atrial
fibrillation |
48 |
1.36
(1.03,1.81)
|
1.36
(4.6)
|
58.3
(43.89,77.44)
|
77667091.94
(77667091.94)
|
|
Acute myocardial infarction |
34 |
7.91
(5.64,11.09)
|
7.82
(202.18)
|
54.78
(39.05,76.86)
|
54251070.65
(54251070.65)
|
|
Haemorrhage |
46 |
1.4
(1.05,1.87)
|
1.4
(5.2)
|
58.14
(43.5,77.69)
|
79751845.5
(79751845.5)
|
|
Cardiac failure |
26 |
2.53
(1.72,3.72)
|
2.51
(23.8)
|
55.64
(37.81,81.89)
|
17466798.23
(17466798.23)
|
|
Cardiac
failure |
42 |
1.42
(1.05,1.92)
|
1.42
(5.16)
|
57.85
(42.71,78.36)
|
80889706.97
(80889706.97)
|
|
Hypertensive crisis |
16 |
10.73
(6.56,17.54)
|
10.67
(139.98)
|
52.16
(31.89,85.31)
|
73988760.86
(73988760.86)
|
|
Blood
pressure fluctuation |
29 |
4.23
(2.93,6.09)
|
4.21
(70.98)
|
55.22
(38.33,79.54)
|
240212796.17
(240212796.17)
|
|
Acute coronary syndrome |
14 |
11.57
(6.84,19.58)
|
11.52
(134.26)
|
51.66
(30.54,87.4)
|
79883667.56
(79883667.56)
|
|
Hypertensive crisis |
19 |
4.43
(2.82,6.95)
|
4.42
(50.17)
|
53.93
(34.36,84.64)
|
251885628.1
(251885628.1)
|
|
Embolism |
12 |
10.56
(5.99,18.63)
|
10.51
(103.17)
|
51.35
(29.11,90.59)
|
72936075.24
(72936075.24)
|
|
Embolism |
11 |
3.36
(1.86,6.08)
|
3.36
(18.21)
|
52.74
(29.18,95.33)
|
191671633.99
(191671633.99)
|
|
Cardiac failure acute |
6 |
7.7
(3.46,17.17)
|
7.69
(34.87)
|
49.8
(22.34,111.02)
|
53349813.43
(53349813.43)
|
|
Blood
pressure inadequately controlled |
7 |
3.45
(1.65,7.25)
|
3.45
(12.17)
|
51.4
(24.48,107.93)
|
196895455.02
(196895455.02)
|
|
Myocarditis |
6 |
5.39
(2.42,12.02)
|
5.38
(21.41)
|
50.31
(22.57,112.14)
|
37385847.36
(37385847.36)
|
|
Aortic
dissection |
6 |
3.39
(1.52,7.56)
|
3.39
(10.11)
|
50.98
(22.88,113.6)
|
193517448.44
(193517448.44)
|
|
Hypertensive urgency |
3 |
97.5
(31.11,305.54)
|
97.39
(281.2)
|
44.16
(14.09,138.39)
|
665011627.88
(665011627.88)
|
|
Left
ventricular dysfunction |
6 |
2.42
(1.09,5.39)
|
2.42
(4.99)
|
51.47
(23.1,114.66)
|
138098680.3
(138098680.3)
|
|
Arterial haemorrhage |
3 |
20.42
(6.57,63.48)
|
20.39
(55.13)
|
46.4
(14.92,144.26)
|
141212345.67
(141212345.67)
|
|
Thrombophlebitis migrans |
5 |
60.58
(24.86,147.6)
|
60.54
(283.79)
|
46.34
(19.02,112.91)
|
3352917345.37
(3352917345.37)
|
|
Aortic thrombosis |
3 |
20.78
(6.68,64.6)
|
20.75
(56.2)
|
46.37
(14.91,144.18)
|
143695979.89
(143695979.89)
|
|
Hypovolaemic shock |
5 |
2.78
(1.16,6.68)
|
2.78
(5.68)
|
50.74
(21.1,122.03)
|
158459126.5
(158459126.5)
|
|
Hypovolaemic shock |
3 |
4.78
(1.54,14.84)
|
4.78
(8.95)
|
48.49
(15.62,150.51)
|
33163815.6
(33163815.6)
|
|
Lymphoedema |
5 |
2.52
(1.05,6.05)
|
2.52
(4.56)
|
50.89
(21.16,122.36)
|
143595777.01
(143595777.01)
|
|
Stress cardiomyopathy |
3 |
4.76
(1.53,14.77)
|
4.75
(8.89)
|
48.49
(15.62,150.53)
|
33010678.21
(33010678.21)
|
|
Systolic
hypertension |
4 |
23.78
(8.87,63.75)
|
23.76
(86.16)
|
47.02
(17.54,126.07)
|
1341166938.15
(1341166938.15)
|
|
Left ventricular dysfunction |
3 |
3.47
(1.12,10.77)
|
3.47
(5.27)
|
48.95
(15.77,151.92)
|
24085491.68
(24085491.68)
|
|
Ventricular hypokinesia |
4 |
3.13
(1.17,8.35)
|
3.13
(5.78)
|
49.93
(18.72,133.17)
|
178457315.04
(178457315.04)
|
|
/ |
|
/ |
/ |
/ |
/ |
|
Hypertensive emergency |
3 |
7.47
(2.4,23.2)
|
7.46
(16.73)
|
47.85
(15.39,148.72)
|
424760772.51
(424760772.51)
|
|
/ |
|
/ |
/ |
/ |
/ |
|
Cardiac discomfort |
3 |
5.75
(1.85,17.87)
|
5.75
(11.74)
|
48.22
(15.52,149.81)
|
327587728.65
(327587728.65)
|
a:only the top 20 repored PT were listed; N:the number of reports of
TKI-associated cardiac AEs; ROR:reporting odds ratio; CI:confidence
interval; PRR:proportional reporting ratio; χ2:chi-squared.
PT, preferred term; AEs, adverse events.
|
a:only the top 20 repored PT were listed; N:the number of reports of
TKI-associated cardiac AEs; ROR:reporting odds ratio; CI:confidence
interval; PRR:proportional reporting ratio; χ2:chi-squared.
PT, preferred term; AEs, adverse events.
|
a:only the top 20 repored PT were listed; N:the number of reports of
TKI-associated cardiac AEs; ROR:reporting odds ratio; CI:confidence
interval; PRR:proportional reporting ratio; χ2:chi-squared.
PT, preferred term; AEs, adverse events.
|
a:only the top 20 repored PT were listed; N:the number of reports of
TKI-associated cardiac AEs; ROR:reporting odds ratio; CI:confidence
interval; PRR:proportional reporting ratio; χ2:chi-squared.
PT, preferred term; AEs, adverse events.
|
a:only the top 20 repored PT were listed; N:the number of reports of
TKI-associated cardiac AEs; ROR:reporting odds ratio; CI:confidence
interval; PRR:proportional reporting ratio; χ2:chi-squared.
PT, preferred term; AEs, adverse events.
|
a:only the top 20 repored PT were listed; N:the number of reports of
TKI-associated cardiac AEs; ROR:reporting odds ratio; CI:confidence
interval; PRR:proportional reporting ratio; χ2:chi-squared.
PT, preferred term; AEs, adverse events.
|
a:only the top 20 repored PT were listed; N:the number of reports of
TKI-associated cardiac AEs; ROR:reporting odds ratio; CI:confidence
interval; PRR:proportional reporting ratio; χ2:chi-squared.
PT, preferred term; AEs, adverse events.
|
a:only the top 20 repored PT were listed; N:the number of reports of
TKI-associated cardiac AEs; ROR:reporting odds ratio; CI:confidence
interval; PRR:proportional reporting ratio; χ2:chi-squared.
PT, preferred term; AEs, adverse events.
|
a:only the top 20 repored PT were listed; N:the number of reports of
TKI-associated cardiac AEs; ROR:reporting odds ratio; CI:confidence
interval; PRR:proportional reporting ratio; χ2:chi-squared.
PT, preferred term; AEs, adverse events.
|
a:only the top 20 repored PT were listed; N:the number of reports of
TKI-associated cardiac AEs; ROR:reporting odds ratio; CI:confidence
interval; PRR:proportional reporting ratio; χ2:chi-squared.
PT, preferred term; AEs, adverse events.
|
a:only the top 20 repored PT were listed; N:the number of reports of
TKI-associated cardiac AEs; ROR:reporting odds ratio; CI:confidence
interval; PRR:proportional reporting ratio; χ2:chi-squared.
PT, preferred term; AEs, adverse events.
|
a:only the top 20 repored PT were listed; N:the number of reports of
TKI-associated cardiac AEs; ROR:reporting odds ratio; CI:confidence
interval; PRR:proportional reporting ratio; χ2:chi-squared.
PT, preferred term; AEs, adverse events.
|
a:only the top 20 repored PT were listed; N:the number of reports of
TKI-associated cardiac AEs; ROR:reporting odds ratio; CI:confidence
interval; PRR:proportional reporting ratio; χ2:chi-squared.
PT, preferred term; AEs, adverse events.
|
a:only the top 20 repored PT were listed; N:the number of reports of
TKI-associated cardiac AEs; ROR:reporting odds ratio; CI:confidence
interval; PRR:proportional reporting ratio; χ2:chi-squared.
PT, preferred term; AEs, adverse events.
|